First Tracks Biotherapeutics

First Tracks Biotherapeutics Debt

The Debt of First Tracks Biotherapeutics (TRAX) as of Oct 19, 2026 is 2.08 M USD. In the previous year, Debt was 1.93 M USD — a change of 8.05% (higher).

Debt

2.08 MUSD

YoY

8.05%

Last updated:

In 2025, First Tracks Biotherapeutics's total debt was 2.08 M USD, a 8.05% change from the 1.93 M USD total debt recorded in the previous year.

The First Tracks Biotherapeutics Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2023
1.78 M USD
Jan 1, 2024
1.93 M USD
Jan 1, 2025
2.08 M USD
The First Tracks Biotherapeutics Debt history
YEARDebtYoY
2.08 MUSD+8.05%
1.93 MUSD+8.33%
1.78 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

First Tracks Biotherapeutics Stock analysis

What does First Tracks Biotherapeutics do? First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company based in San Diego, United States, developing immunology therapeutics for autoimmune and inflammatory diseases. The company focuses on innovative treatments including ANB033, a novel anti-CD122 antagonist targeting IL-15 and IL-2 receptors, Rosnilimab, which selectively depletes pathogenic T cells, and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells. Founded in 2019, it operates in the United States with a focus on advancing therapies for complex immune conditions. First Tracks Biotherapeutics is one of the most popular companies on Eulerpool.

Debt Details

Understanding First Tracks Biotherapeutics's Debt Structure

First Tracks Biotherapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing First Tracks Biotherapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to First Tracks Biotherapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in First Tracks Biotherapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about First Tracks Biotherapeutics stock

Debt of First Tracks Biotherapeutics is 2.08 M USD in 2025.

Debt of First Tracks Biotherapeutics changed from 1.93 M USD to 2.08 M USD, representing a 8.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt First Tracks Biotherapeutics since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's First Tracks Biotherapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — First Tracks Biotherapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — First Tracks Biotherapeutics